DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Department of Defense
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate p
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Next 90 days
Posted
05/04/2026
Closes
2026-09-30
Eligibility
Eligibility
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Program
Funding area
Science and Technology and other Research and Development - ST
Opportunity #
HT942526ALSRPTDA
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov